SCHAUMBURG, Ill., May 24, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced its planned launch of piperacillin and tazobactam for injection, the generic form of Zosyn®, in three distinct single dose vial forms. Piperacillin and tazobactam is used for the treatment of patients with moderate to severe bacterial infections. According to IMS data, the U.S. market for injectable piperacillin and tazobactam approximated $749 million.
"Our introduction of generic Zosyn® will add a very significant anti-infective to our rapidly expanding product portfolio," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "Our piperacillin and tazobactam vials will provide another important source of this frequently prescribed antibiotic to the medical community. Piperacillin and tazobactam is widely used in hospital settings because of its efficacy against a broad range of bacteria. Our product also includes the benefits of our PreventIV Measures™ packaging and labeling, designed to aid in the reduction of medication errors."
About Piperacillin and Tazobactam for Injection
Piperacillin and tazobactam is indicated for the treatment of patients with moderate to severe infections caused by piperacillin-resistant, piperacillin and tazobactam susceptible, beta-lactamase producing strains of the designated microorganisms in a number of conditions such as: appendicitis (complicated by rupture or abscess), peritonitis, uncomplicated and complicated skin and skin structure infections, postpartum endometritis or pelvic inflammatory disease, community-acquired pneumonia (moderate severity only) and nosocomial pneumonia (moderate to severe). Please see DOSAGE and ADMINISTRATION for complete details.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent operates a global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, which quickly yields an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.
To learn more about Sagent, please visit www.SagentPharma.com.
This press release contains a number of forward-looking statements. Words, and variations of words such as "expect," "goals," "plans," "believe," continue," "may," "will," and similar expressions are intended to identify our forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from those indicated in our forward-looking statements. Please also see our risk factors, as they may be amended from time to time, set forth in our filings with the SEC, including the IPO prospectus filed by Sagent on April 21, 2011 and our most recent 10-Q. Sagent disclaims and does not undertake any obligation to update or revise any forward-looking statement in this press release, except as required by applicable law or regulation.
CONTACT: Investor Contact: Ronald Pauli, Sagent (847) 908-1604 Media Contact: Geoff Curtis, WCG (312) 646-6298